BKS Advisors LLC held its position in Rockwell Medical, Inc. (NASDAQ:RMTI) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 237,958 shares of the company’s stock at the end of the second quarter. BKS Advisors LLC owned about 0.46% of Rockwell Medical worth $1,887,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in RMTI. Wells Fargo & Company MN raised its stake in shares of Rockwell Medical by 0.5% in the first quarter. Wells Fargo & Company MN now owns 115,738 shares of the company’s stock valued at $725,000 after buying an additional 550 shares in the last quarter. Balasa Dinverno & Foltz LLC raised its stake in shares of Rockwell Medical by 5.8% in the second quarter. Balasa Dinverno & Foltz LLC now owns 54,300 shares of the company’s stock valued at $431,000 after buying an additional 3,000 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Rockwell Medical by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 78,948 shares of the company’s stock valued at $517,000 after buying an additional 4,000 shares in the last quarter. American International Group Inc. raised its stake in shares of Rockwell Medical by 7.1% in the first quarter. American International Group Inc. now owns 29,509 shares of the company’s stock valued at $185,000 after buying an additional 1,955 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Rockwell Medical by 9.7% in the first quarter. Geode Capital Management LLC now owns 371,700 shares of the company’s stock valued at $2,326,000 after buying an additional 32,964 shares in the last quarter. 21.37% of the stock is currently owned by institutional investors.

Shares of Rockwell Medical, Inc. (NASDAQ RMTI) opened at 6.62 on Wednesday. The firm’s market capitalization is $342.52 million. Rockwell Medical, Inc. has a 12-month low of $3.55 and a 12-month high of $8.98. The company has a 50-day moving average price of $6.97 and a 200 day moving average price of $6.94.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Wednesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The business had revenue of $13.24 million during the quarter, compared to the consensus estimate of $13.05 million. Rockwell Medical had a negative net margin of 39.68% and a negative return on equity of 42.22%. The business’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.11) earnings per share. Equities research analysts expect that Rockwell Medical, Inc. will post ($0.44) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.watchlistnews.com/rockwell-medical-inc-rmti-stake-held-by-bks-advisors-llc/1531956.html.

RMTI has been the subject of several research reports. ValuEngine lowered Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. BidaskClub upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, Ifs Securities initiated coverage on Rockwell Medical in a report on Monday, August 14th. They set a “strong-buy” rating and a $11.00 price target for the company. Three research analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Rockwell Medical currently has a consensus rating of “Hold” and a consensus price target of $8.38.

About Rockwell Medical

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Institutional Ownership by Quarter for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.